Sprouty1 (Spry1) is a negative regulator of fibroblast growth factor signaling with a potential tumor suppressor function in prostate cancer (PCa). Spry1 is downregulated in human PCa, and Spry1 expression can markedly inhibit PCa proliferation in vitro. We have reported DNA methylation as a mechanism for controlling Spry1 expression. However, promoter methylation does not seem to explain gene silencing in all PCa cases studied to suggest other mechanisms of gene inactivation, such as alterations in trans-acting factors and/or post-transcriptional activity may be responsible for the decreased expression in those cases. Binding sites for Wilm's tumor (WT1) transcription factors EGR1, EGR3 and WTE are highly conserved between the mouse and human Spry1 promoter regions, suggesting an evolutionary conserved mechanism(s) involving WT1 and EGR in Spry1 regulation. Spry1 mRNA contains multiple microRNA (miRNA) binding sites in its 3 0 UTR region suggesting post-transcriptional control. We demonstrate that Spry1 is a target for miR-21-mediated gene silencing. miRNA-based therapeutic approaches to treat cancer are emerging. Spry1 is highly regulated by miRNAs and could potentially be an excellent candidate for such approaches.
Introduction
Prostate cancer (PCa) is the second most common malignancy and the second leading cause of cancer deaths in men in the United States. There is abundant evidence to indicate that inappropriate activation of fibroblast growth factor (FGF) receptor signaling has a critical role in the initiation and progression of PCa (for review see Kwabi-Addo, Ozen and Ittmann 1 ). Sprouty (Spry) was originally identified in Drosophila as a negative regulator of FGF signaling during tracheal development. 2 Subsequent studies have shown Spry to be a general inhibitor of growth factor-induced receptor tyrosine kinase (RTK) signaling pathways involved in Drosophila development and organogenesis. [3] [4] [5] While Drosophila has only one Spry gene, at least four Spry homologs (Spry1-4) have been found in humans and mice. 2, 6, 7 Mammalian Spry inhibits growth factor-i nduced cell responses by inhibiting the RTK-dependent Ras/mitogen-activated protein kinase signaling pathway. [8] [9] [10] Several mechanisms for Spry inhibition of the RTK/Ras/mitogen-activated protein kinase pathway have been proposed, including blocking the interaction of the Grb2/SOS complex with the docking protein, FRS2 3, 8 or the inhibition of Raf. [11] [12] [13] Another characteristic of the Spry inhibitors is their regulation by growth factors in a negative feedback loop, that is, their expression is dependent on the signaling pathway that they regulate.
14 Specifically, growth factors regulate both the level of Spry transcript 6 and, in some systems, the recruitment of Spry proteins to the plasma membrane. 15 However, unlike Spry1, Spry2 and Spry4, whose expression can be inhibited in response to the downregulation of FGF signaling with the FGF receptor inhibitor SU5402, Spry3 is not inhibited by SU5402 treatment, suggesting that Spry3 might be involved in the regulation of another signaling pathway. 14, 16 Indeed, recent reports indicate that Spry3 has a role in axonal branching in a brain-derived neurotrophin factor-dependent manner; 14, 16 however, there is very little information about the role of Spry3 in PCa. Given that Spry1, 2 and 4 proteins can inhibit FGF signaling, they can potentially decrease the biological activities of FGFs in PCa cells and inhibit their ability to promote cancer progression.
We have previously shown by immunohistochemical and quantitative real-time PCR (RT-PCR) analysis that Spry1 and Spry4 are downregulated in a subset of PCas tissues when compared with normal prostate tissues. 17, 18 We have also demonstrated that transient and sustained increased expression of Spry1 markedly inhibits PCa cell proliferation 17 whereas the sustained increased expression of Spry4 inhibited PCa cell migration. 18 McKie et al. 19 have observed that Spry2 expression is reduced in clinical PCa tissues when compared with BPH. The accumulating data indicate distinct differences in the functional roles for Spry1 and Spry4 in PCa cell lines.
The decrease in Spry expression in the human PCa, despite elevated levels of FGF ligands and FGF receptors, implies a loss of an important growth regulatory mechanism in PCas that may potentiate the effects of increased FGF and FGF receptor expression in PCa tissues and may represent a novel mechanism that facilitates aberrant RTK signaling in prostate carcinogenesis.
We have previously demonstrated that DNA methylation in the Spry1 promoter region is responsible for downregulating Spry1 expression in PCa. 20 However, promoter methylation does not seem to explain gene silencing in all PCa cases studied. For instance, in some PCa cases, where we detected low DNA methylation in the cancer tissues compared with the normal tissues, we also observed low Spry1 expression to suggest that other mechanisms of gene inactivation such as alterations in trans-acting factors and/or post-transcriptional activity may be responsible for the decreased expression in those cases.
The purpose of the present study is to investigate the relative contribution of trans-acting factors and posttranscriptional regulation of Spry1 in PCa. Our data support a potential role of mir-21 in post-transcriptional regulation of Spry1 in PCa cells.
Materials and methods

Cell Culture and treatment
The human PCa cell lines, PC3, DU145 and LNCaP, and the immortalized normal prostate epithelial cell line pNT1A were obtained from the American Type Culture Collection (Manassas, VA, USA). All cell lines were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA) unless otherwise stated.
LNCaP cells were treated with 10 ng ml À1 of lipopolysaccharide (Sigma-Aldrich, St Louis, MO, USA) for 24 h in complete medium without antibiotics. Treated and untreated cells were harvested and extracted RNA was used in quantitative RT-PCR with Cancer miRNA Array (SA BioSciences, Frederick, MD, USA) according to the manufacturer's protocol.
Transfections and antibodies
LnCaP, PNT1A, DU145 and PC3 cells were transiently transfected with Spry1 construct (pcDNA-Spry1 17 ) or vector only (pcDNA3.1), shRNA-GATA-2, shRNA-GATA-4, shRNA-EGR-1, shRNA-EGR-2 or vector only (PLKO), GATA 4 (pCMV6-GATA4; Origene (Rockville, MD, USA)) of EGR2 (pCMV6-EGR2; Origene) of the vector only (pCMV6; Origene). Cells were also transfected with anti-miR-21, or anti-microRNA (miRNA) negative control. All transfections were done using Lipofectamine 2000 reagent (Invitrogen) and according to manufacturer's protocol. After 24, 48 or 72 h, cells were harvested and either miRNA was extracted using miRNA isolation kit (Ambion Austin, TX, USA) or total RNA was extracted using TRIzol reagent (Invitrogen). In addition, total proteins were extracted and used in western blot analysis as previously described. 17 All shRNAs and anti-miRs were purchased from Origene and Applied Biosystems (Foster City, CA, USA), respectively, unless otherwise stated.
Antibodies used for western blotting, electrophoretic mobility shift assays (EMSAs) and chromatin immunoprecipitation (ChIP) were the following: rabbit anti-Spry1, mouse anti-actin, rabbit anti-Egr-1, goat anti-Egr-2, goat anti-rabbit GATA-2, rabbit anti-GATA-4, rabbit anti-p-ERK 1 2 (Thr 202/Tyr 204), anti-PBX1 rabbit polyclonal immunoglobin G, anti-SP1 mouse monoclonal immunoglobin G and anti-HNF4a goat polyclonal immunoglobin G. Anti-acetyl-Histone H4 rabbit antiserum was purchased from Upstate Biotech (Lake Placid, NY, USA). All antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA, USA) unless otherwise stated.
cDNA synthesis and quantitative RT-PCR
Total RNA was used in first-strand DNA (cDNA) synthesis using Invitrogen SuperScript first-strand synthesis for reverse transcription-PCR and according to the manufacturer's protocol. Small species-enriched RNA (miRNA) was extracted and converted to cDNA using Taqman microRNA kit (Applied Biosystems) and according to manufacturer's instruction. Taqman primer sequences designed as corresponding to mir-21 were used and U6 was used as a normalizing control. RT-PCR was carried out in a Bio-Rad iCycler real-time thermal cycler (Hercules, CA, USA) as described previously 17 using LightCycler fast start DNA master cyber green I (Roche Applied Science, Indianapolis, IN, USA). Expression of Spry1 and b-actin were evaluated according to manufacturer's protocol. Alternatively, RT-PCR analysis of miRNA was carried out using the cDNA product along with TaqMan primers and other PCR reagents in the PCR Universal Master Mix Kit (Applied Biosystems). The PCR conditions included initial incubation at 50 1C for 2 min and denaturing at 95 1C for 5 s and 60 1C for 1 min. Each sample was measured in duplicate.
Nuclear extracts and oligonucleotide probe preparation and EMSAs
Nuclear extracts were prepared from PC3, DU145, LNCaP and PNT1A using RIPA lysis buffer (Thermo Scientific, Rockford IL, USA). Oligonucleotide sequences were synthesized by Sigma Genosys (St Louis, MO, USA). Oligonucleotide sequences encompassing binding sites for wild type or mutant (mut) transcription factors (TFs) were synthesized as sense (F) or antisense (R) strands:
Each oligonucleotide sense strand was end-labeled with [g- P] dATPs were removed by purifying the probes using a G-25 (Fine) Sephadex Quick spin columns (Roche). The EMSAs were carried out as described previously. 21 Briefly, the 32 P-labeled oligonucleotide probes were incubated with or without nuclear extract in a total reaction volume of 25 ml containing the binding assay buffer (50 mM Tris-HCl, pH 7.4; 50 mM NaCl; 1 mg ml À1 bovine serum albumin; 5 mg ml À1 poly dI-dC; 20% glycerol). The reactions were started by the addition of nuclear extract (5 ml per reaction) and incubated at room temperature for 30 min. Competition reactions were preincubated in the binding buffer for 30 min at room temperature with 100-fold molar excess of the corresponding unlabeled oligonucleotides followed by 30 min incubation at room temperature with the labeled oligonucleotide. For supershift analysis, 1 ml of antibody was pre-incubated with the binding buffer for 45 min at room temperature before the addition of the 32 P-labeled probe. The bound and free DNA were resolved by electrophoresis through a 5% polyacrylamide gel at 175 V in 0.5 Â tris-borate-EDTA at room temperature for 2.5 h. Dried gels were exposed to Kodak Bio-Max film (St Louis, MO, USA) at À80 1C with intensifying screens.
Chromatin immunoprecipitation
ChIP assays were performed as described previously. 22 For PCR reaction, DNA solution (50 ng) was used as a template with Spry1 Fwd 5 (forward) and Rev (reverse) primers as previously described. 20 
Results
Comparative sequence analysis of the Spry1 promoter locus
To characterize the Spry1 promoter region, we searched for TF binding sites using the MatInspector program. 23 We analyzed 2 kb of the genomic sequence upstream of the Spry1 transcription start site, 20 using computer-based analysis (MatInspector software from Genomatix; http:// www.Genomatix.de). We found potential binding sites for several TFs including GATA1, 24 EGR, 25 SPI, 26 PBX1 27 and HNF4 28 in the proximal promoter region. The human and murine Spry1 5 0 -flanking region upstream of their transcription start sites were aligned for sequence comparison. Over the entire 5 0 -flanking region of the human Spry1 promoter, only a very short region in the promoter (between À112 and þ 1 relative to the transcription) showed B94% degree of homology with the mouse Spry1 promoter. As illustrated in Figure 1 , Wilm's tumor (WT1) TF binding sites EGR1 and 3 29 and WTE 30 are conserved between the two species. Interestingly, the nucleotide sequences immediately upstream from the EGR motif diverge in these species. Furthermore, we did not see any sequence homology between the human Spry1 promoter region and that of the published Spry2 31 or Spry4 32 promoters. The high sequence homology in the Spry1 promoter of the mouse and human indicates an evolutionary conserved mechanism(s) involving WT1 and EGR TFs in Spry1 gene regulation.
Electrophoretic mobility shift assay
To verify the binding interaction of the Spry1 consensus sequence in vivo, we performed EMSA using designed consensus radiolabeled oligonucleotide probes to recognize EGR1, PBX1, HNF-4 and SP1 and nuclear extracts prepared from either LNCaP, PC-3 or pNT1A. As all three cell lines demonstrated a similar band-shift pattern with each probe, only results using nuclear extracts from LNCaP cells are shown in Figure 2a . Three protein-DNA complexes (C1, C2 and C3) were formed with each of the oligonucleotide probes. These complexes represented sequence-specific interactions of proteins within this region, as the addition of 100-fold molar excess of the corresponding unlabeled oligonucleotide probe was able to compete away these complexes. To characterize these complexes further, supershift EMSA was conducted using specific antibodies. The addition of anti-SP1 antibody clearly abrogated the formation of C2, while the addition of anti-PBX1 and anti-HNF4 antibodies reduced the signal intensity of the respective C2 complex, suggesting that the C2 complex is formed with SP1, PBX1 and HNF4, respectively. We did not see any significant effect of the addition of anti-EGR antibody on the protein-DNA complexes. However, when the EGR1 consensus binding sequence was mutated (mut EGR1), we observed a new complex migrating very close with complex C2. Cold competition assay with wild-type EGR1 oligonucleotide competed out complex C2 totally but only partially competed the new complex. Furthermore, supershift assay successfully competed C2. This indicates that EGR1 protein preferentially recognizes and interacts with the wild-type EGR1 consensus binding sequence.
Chromatin immunoprecipitation
We next studied whether these TFs were bound to the Spry1 promoter in vivo using ChIP assay. Figure 2b showed that indeed these TFs were bound to Spry1 promoter in vivo as demonstrated by the same PCR product in the assay precipitation with different antibodies compared with the Anti-acetyl-Histone H4 antibody control (positive control). Conversely, precipitation with normal goat immunoglobin G (negative control) did not show any binding. These studies clearly demonstrate that Spry1 proximal promoter region contains several sequence motifs (that is, EGR, GATA, SP1, PBX1 and HNF4), which are specifically recognized by known as well as uncharacterized TFs and are functionally important and likely to be responsible for driving the basal transcription of the Spry1 gene. 
Impact of EGR and GATA activity on Spry1 expression
To verify the involvement of TF binding activity in regulating Spry1 expression, we investigated two TFs; EGR and GATA. We studied EGR because the EGR binding site appears to be highly conserved between human and mouse, and GATA because of its consensus binding site in Spry1 proximal promoter region. We carried out transient transfections in prostate cell lines with shRNA duplexes corresponding to EGR1, EGR2, GATA2 and GATA4. Western blot analyses were performed using Spry1 antibody and total cell lysates in order to examine the silencing effect of the EGR1, EGR2, GATA2 and GATA4 shRNA transfections on Spry1 protein expression. As all shRNA transfections demonstrated a similar knockdown effect in the PCa cells, only results from EGR2 and GATA4 shRNA transfections are shown (Figure 3a) . On the other hand, when we overexpressed EGR2 and GATA4 in prostate cell lines, this was accompanied by increase in Spry1 protein level as detected by western blot analysis (Figure 3b) . The results clearly showed that EGR2 and GATA4 expression co-relate with Spry1 expression as the blockade of EGR2 and GATA4 by small inhibitory RNA also inhibits Spry1 protein expression whereas the increased expression of EGR2 and GATA4 resulted in increased expression of Spry1.
The role of miR-21 expression and Spry1
Next, we assessed whether Spry1 expression is inhibited by miRNA because Spry1 mRNA contains several predicted microRNA binding sites. 33 We focused on mir-21 because when LNCaP cells, which expressed very low amounts of mir-21 (Figure 4a ), were treated with bacterial lipopolysaccharide to induce inflammation, mir-21 was one miRNA that was significantly upregulated (Figure 4b ). When prostate cell lines were transiently transfected with anti-miR-21, we observed a significant increase in Spry1 protein expression when compared with scrambled control transfection ( Figure 4c ). As miRNAs have been shown to regulate mRNAs by binding to their 3 0 -UTRs and enhancing degradation or preventing translation, 34 we reason that miR-21 affects Spry1 expression by degrading mRNA transcript and thereby repressing translation. Spry1 expression is dependent on the ERK signaling Transcriptional and post-transcriptional regulation of Sprouty1 M Darimipourain et al pathway; 35 we therefore used phosphor-ERK1/2 as a marker for monitoring changes in Spry1 function that would be regulated by changes in its levels. As shown in Figure 4c , increased expression of Spry1 in prostate cells in response to anti-miR-21 treatment led to a marked decrease in basal phosphor-ERK1/2 normalized to the total ERK. In other words, the increased expression of miR-21 in PCa cells induces the downregulation of important inhibitory signals, including Spry1, and this may potentially facilitate tumor progression.
Discussion
In the present study, we have identified a highly conserved nucleotide binding site for the early growth response (EGR1) in the human and mouse Spry1 promoter region, which underscores the importance of this motif in the regulation of the Spry1 gene expression. We have used EMSA and ChIP assays to demonstrate interaction of several cis-elements within the human Spry1 promoter region (including GATA2 & 4, EGR1 & 2, SP1, PBX1 and HNF4) that confers responsiveness to growth factor signaling. In the human prostate, there is strong evidence to suggest that EGR1 overexpression is involved in PCa progression. 36 For example, EGR1 expression levels are elevated in human prostate carcinomas in proportion to grade and stage. On the other hand, antisense oligonucleotides that block EGR1 function revert transformation of PCa cells in vitro and delay PCa progression in vivo. 37 We have observed a direct correlation between Spry1 and EGR2 expression: a decrease in Spry1 expression in response to EGR2 knockdown, whereas Spry1 expression increased in response to EGR2 overexpression. Similarly, we observed a direct correlation of Spry1 expression with GATA4; knockdown of GATA4 decreased Spry1 expression, whereas the overexpression of GATA4 increased Spry1 expression in PCa cell lines. One study has reported that GATA2 is expressed in substantial proportion of PCas and that high level of GATA2 expression is associated with biochemical recurrence and distant metastatic progression. 38 It appears that both EGR and GATA transcriptions are upregulated in PCa even though Spry1 expression is downregulated in a significant number of PCa samples. Indeed, several TFs with potential binding sites in the proximal regions of Spry1 promoter act as transcriptional activator [26] [27] [28] in PCa. Thus, additional studies are needed in order to clarify the Transcriptional and post-transcriptional regulation of Sprouty1 M Darimipourain et al role of these TFs in Spry1 regulation in PCa. However, the observation that Spry1 is a direct target for miR-21 regulation in addition to DNA methylation control 20 clearly demonstrates a strong epigenetic control for Spry1 expression in PCa. One of the emerging fields in cancer research is miRNAs. Several miRNA expression studies and functional experiments in cancer have shown an important role for miRNAs in the disease initiation and progression and their potential as diagnostic, prognostic and predictive biomarkers. 32 In PCa, higher levels of miR-21 have been reported in blood plasma of patients in comparison with healthy controls. 33 This finding is in line with published data describing an oncogenic role of miR-21 in various cancers. 34 One of the factors that could lead to increase expression of miR-21 in PCa might be in response to chronic inflammation. The increased mir-21 expression in turn may exacerbate disease progression by repressing the translation of important regulatory genes including Spry1as described in this manuscript.
Conclusion
In the current studies, we have investigated the transcriptional and post-transcriptional regulation of Spry1 in human prostate cells. While Spry1 shows a highly conserved binding site for EGR and GATA, the role of these TFs in regulating Spry1 expression is not clear. On the other hand, we observe downregulation of Spry1 by miR-21 expression. Taken together with our previous observation that DNA methylation has a role in Spry1 expression, our observation strongly indicates that epigenetic mechanism has an important role in Spry1 regulation in human PCa. 
